GlaxoSmithKline (GSK) is set to trial an investigational rheumatoid arthritis drug otilimab for the treatment of pneumonia caused by Covid-19 infection.
GSK identified the drug after screening its portfolio and pipeline for potential against Covid-19. The company acquired the rights to otilimab from German biotech firm Morphosys in 2013, noted Reuters.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to a company spokesman, otilimab could potentially ease the effect of the coronavirus on the lungs but not suppress it directly.
